Latest filing published 27 Apr 2026 for Amicus Therapeutics, INC., €1.6M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Samantha Prout, listed as senior executive, appears in our data through filings on Amicus Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 16 filings, for trades running from 23 August 2021 to 27 April 2026.
No open-market purchase appears, only 4 sales worth €555k. Besides market trades, the filings include 9 share grants and 2 option exercises.
The latest filing, published on 27 April 2026, reports a transaction of €1.6M in Amicus Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations